Skip to content
ADMAAdma Biologics, Inc.

Earnings

When Adma Biologics, Inc. reports, what it reported each quarter, and how the stock took the results.

64 quarters. Sep 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 24, after the close

Wed, Feb 24, 2027in 99 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 25 – Mar 26

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$139.16M
Revenue, change from a year earlier: Q3 2026 +5.1%, Q2 2026 +2.0%, Q1 2026 −0.3%, Q4 2025 +18.4%
Net income
$49.38M
Net income, change from a year earlier: Q3 2026 +36.9%, Q2 2026 +10.5%, Q1 2026 +68.5%, Q4 2025 −55.9%
EPS
—
EPS, change from a year earlier: Q3 2026 +46.7%, Q2 2026 +14.3%, Q1 2026 +72.7%, Q3 2025 ±0.0%

Quarter by quarter

Q3 2026$141.10M+5.1% vs Q3 2025

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release+26.2%by the close of Nov 5
    Revenue
    $141.10M
    +5.1%
    Net income
    $49.88M
    +36.9%
    EPS
    $0.22
    +46.7%
    Total revenue for the quarter ended September 30, 2026 was $141.1 million, compared with $134.2 million for the quarter ended September 30, 2025 and $124.4 million in the second quarter of 2026, representing growth of 5% year-over-year and 13% sequentially.
  2. Q2 2026Aug 5, 2026, after the closeThe release+8.2%by the close of Aug 6
    Revenue
    $124.40M
    +2.0%
    Net income
    $37.82M
    +10.5%
    EPS
    $0.16
    +14.3%
  3. Q1 2026May 6, 2026, after the closeThe release16.3%by the close of May 7
    Revenue
    $114.49M
    −0.3%
    Net income
    $45.33M
    +68.5%
    EPS
    $0.19
    +72.7%
  4. Q4 2025Feb 25, 2026, after the closeThe release3.5%by the close of Feb 26
    Revenue
    $139.16M
    +18.4%
    Net income
    $49.38M
    −55.9%
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q$141.10M+5.1%$0.22+26.2%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q$124.40M+2.0%$0.16+8.2%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 6, 202636 d10-Q$114.49M−0.3%$0.1916.3%
FY 2025
Q4 2025derivedDec 31, 2025Feb 25, 2026 · after-hoursFeb 25, 202656 d10-K$139.16M+18.4%—3.5%
Q3 2025Sep 30, 2025Nov 5, 2025 · after-hoursNov 5, 202536 d10-Q$134.22M+12.0%$0.158.7%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q$121.98M+13.8%$0.149.8%
Q1 2025Mar 31, 2025May 7, 2025 · after-hoursMay 7, 202537 d10-Q$114.80M+40.2%$0.1110.2%
FY 2024
Q4 2024derivedDec 31, 2024Mar 3, 2025 · after-hoursMar 18, 202577 d10-K$117.55M+59.1%—+7.3%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$119.84M+78.1%$0.15+14.8%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q$107.19M+78.3%$0.13+30.9%
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q$81.88M+43.9%$0.08—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026041977
10-QAug 5, 2026031445
10-QMay 6, 2026019336
10-KFeb 25, 2026006815
10-QNov 5, 2025040578
10-QAug 6, 2025029177
10-QMay 7, 2025017747
10-KMar 18, 2025009257
10-QNov 7, 2024045693
10-QAug 8, 2024036432

Provenance

ProvenanceData status and checks

Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR